At the start of 2016, the FDA approved brand-new migraine treatment: Onzetra Xsail. Although it shares an active ingredient with Imitrex (sumatriptan), the way you use Onzetra is unique, and offers another option for getting you migraine relief.
There are many medications already on the market to treat migraines before and after they begin. The standard in migraine treatment is a group of medications known as “triptans.” Some popular examples include:
- Imitrex (sumatriptan)
- Zomig (zolmitriptan)
- Maxalt (rizatriptan)
- Amerge (naratriptan)
- Axert (almotriptan)
- Frova (frovatriptan)
- Relpax (eletriptan)
Is there anything unique about Onzetra?
Yes. Onzetra is a nasal powder, but it is not sprayed or inhaled through the nostrils. So, how does it work then? Onzetra uses the Xsail breath-powered delivery device, which delivers a low dose of sumatriptan powder into the nose.
How is Onzetra Xsail used?
You will blow into the device with your mouth to deliver medication into your nose through a disposable nosepiece.
The recommended dose is 1 puff per nostril (11 mg in each nostril) for a total of 22 mg.
You shouldn’t exceed 2 doses (44 mg total) in a 24-hour period, and the doses should be separated by at least 2 hours.
What are the side effects of Onzetra?
The most common side effects include abnormal taste after use, nasal discomfort, and a runny or stuffy nose.
When will Onzetra Xsail be available?
At this time the availability of Ozentra Xsail is pending but is set to be available to patients in the next fe months.
Want more information?
See the press announcement from the manufacturer Avanir Pharmaceuticals here.